Altered fractionation radiotherapy in head and neck cancer: Clinical issues and pitfalls of "evidence-based medicine"

Tumori

Volumn 91, Issue 1, 2005, Pages 30-39

  Antognoni, Paolo ^a,f   Corvò, Renzo ^b   Zerini, Dario ^a,c   Orecchia, Roberto ^d,e  

^a IRCCS MULTIMEDICA   (Italy)

^b Ospedale di Sanremo   (Italy)

^c Sc di Spec in Radioterapia   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^f Service of Radiotherapy   (Italy)

Author keywords

Accelerated radiotherapy; Head and neck cancer; Hyperfractionated radiotherapy

Indexed keywords

AMIFOSTINE; RADIOPROTECTIVE AGENT;

CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSENSUS; EVIDENCE BASED MEDICINE; HEAD AND NECK CANCER; HUMAN; META ANALYSIS; MORBIDITY; MUCOSA INFLAMMATION; OUTCOMES RESEARCH; PATIENT SELECTION; QUALITY OF LIFE; RADIATION DOSE; RADIATION DOSE FRACTIONATION; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; TECHNIQUE; XEROSTOMIA;

EID: 16344390211     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160509100107     Document Type: Review

References (53)

1. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK: A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare HF and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys, 48: 7-16, 2000.
2. Bourhis J, Syz N, Oversaard J, Ang KK, Dische S, Horiot J, Hilniak A, Poulsen M, O'Sullivan B, Dobrowski W, Fallai C, Pinto L, Skladowski K, Hay JH, Fu KK, Sylvester R, Pignon J: Conventional vs modified fractionated radiotherapy in head & neck squamous cell carcinoma: a meta-analysis based on individual patient data (abst). Int J Radiat Oncol Biol Phys, 54 (Suppl): 71-72, 2002.
3. Ang KK: Altered fractionation trials in head and neck cancer. Sem Radiat Oncol, 8: 230-236, 1998.
4. Bernier J, Bentzen SM: Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck cancer oncology. Eur J Cancer, 39: 560-571, 2003.
5. Baumann M, Saunders MJ, Joiner M: Modified fractionation. In: Basic clinical radiobiology, Steel GG (Ed), pp 147-157, Oxford University Press, London, 2002.
6. Thames HD, Peters LJ, Withers HR, Fletcher G: Accelerated fractionation vs. hyperfractionation: rationales for several treatments per day. Int J Radiat Oncol Biol Phys, 9: 127-138, 1983.
7. Thames HD, Bentzen SM, Turesson I, Overgaard M, Van den Bogaert W: Time-dose factors in radiotherapy: a review of the human data. Radiother Oncol, 19: 219-235, 1990.
8. Withers HR, Horiot JC: Hyperfractionation. In: Innovations in radiation oncology, Withers HR, Peters LJ (Eds), pp 223-230, Springer-Verlag, Berlin, 1988.
9. Horiot JC, Le Fur R, N'Guyen T: Hyperfractionated versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol, 25: 231-241, 1992.
10. Skladowski K, Maciejewski AW, Golen M, Pilecki AW, Przeorek AW, Tarnawski R: Randomized clinical trial on 7-day continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3-year tumour control and normal tissue toxicity. Radiother Oncol, 55: 101-110, 2000.
11. Overgaard J, Hansen HS, Specht L, Overgaard M, Grai C, Andersen E, Bentzen J, Bastholt L, Hansen O, Johansen J, Andersen L, Fevensen J: Five compared with six fractions per week of conventional radiotherapy of squamous cell carcinoma of the head and neck: DAHANCA 6 & 7 randomised controlled trial. Lancet, 362: 933-940, 2003.
12. Marcial V, Pajak T, Chang C, Tupchong L, Stetz J: Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Oncology Group (RTOG). Int J Radiat Oncol Biol Phys, 13: 41-47, 1987.
13. Datta NR, Choudry AD, Gupta S, Bose AK: Twice a day versus once a day radiation therapy in head and neck cancer (abstr). Int J Radiat Oncol Biol Phys, 17 (Suppl 1): 132, 1989.
14. Sanchiz F, Millà A, Torner J, Bonet F, Artola N, Carreno L, Moya L, Riera D, Ripol S, Cirera L: Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys, 19: 1347-1350, 1990.
15. Pinto L, Canary P, Arayo C, Bacelar S, Souhami L: Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys, 21: 557-562, 1991.
16. Stuschke M, Thames HD: Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys, 37: 259-267, 1997
17. Beck-Bornholdt HP, Dubben HH, Liertz-Petersen C, Willers H: Hyperfractionation: where do we stand? Radiother Oncol, 43: 1-21, 1997.
18. Jackson SM, Weir LM, Hay JH, Tsang VHY, Durham JS: A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer. Radiother Oncol, 43: 39-46, 1997.
19. Van den Bogaert W, Van der Schueren E, Horiot JC, De Vilhena M, Schraub S, Svoboda V, Arcangeli G, De Pauw M, Van Glabbeke M: The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: prognostic factors. Radiother Oncol, 35: 91-99, 1995.
20. Horiot JC, Bontemps P, van den Bogaert W, Le Fur R, van den Weijngaert D, Bolla M, Bernier J, Lusinchi A, Stuschke M, Lopez-Torrecilla J, Begg AC, Pierart M, Collette L: Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol, 44: 111-121, 1997.
21. Johnson CR, Schmidt-Ullrich RK, Arthur DW, Huang DT, Duffy EW: Standard once-daily versus thrice-daily concomitant boost accelerated superfractionated irradiation for advanced squamous cell carcinoma of the head and neck: preliminary results of a prospective randomized trial (abstr). Int J Radiat Oncol Biol Phys, 32 (Suppl 1): 162, 1995.
22. Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M: A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol, 44: 123-136, 1997.
23. Poulsen MG, Denham JW, Peters LJ, Lamb DS, Spry NA, Hindley A, Krawitz H, Hamilton C, Keller J, Tripcony L, Walker Q: A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study. Radiother Oncol. 60: 113-122, 2001.
24. Olmi P, Crispino S, Fallai C, Torri V, Rossi F, Bolner A, Amichetti M, Signor M, Taino R, Squadrelli M, Colombo A, Ardizzoia A, Ponticelli P, Franchin G, Minatel E, Gobitti C, Atzeni G, Gava A, Flann M, Marsoni S: Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy: a multicenter randomized trial. Int J Radiat Oncol Biol Phys, 55: 78-92, 2003.
25. Awwad HK, Khafaagy Y, Barsoum M: Accelerated versus conventional fractionation in the postoperative irradiation of locally advanced head and neck cancer: influence of tumour proliferation. Radiother Oncol, 25: 261-266, 1992.
26. Ang KK, Trotty A, Brown B, Garden AS, Foote R, Morrison WH, Geara FB, Klotch D, Goepfert H, Peters LJ: Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys, 51: 571-578, 2001.
27. Sanguineti G, Richetti A, Bignardi M, Corvò R, Gabriele P, Sormani MP, Antognoni P: Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter phase III study. Int J Radiat Oncol Biol Phys, 00: 000-000, 2005 (in press).
28. Kaanders JHAM, van der Kogel A, Ang KK: Altered fractionation: limited by mucosal reactions? Radiother Oncol, 50: 247-260, 1998.
29. Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilberberg MD: Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol, 66: 253-262, 2003.
30. Denham JW, Peters LJ, Johansen J, Poulsen M, Lamb DS, Hindley A, O'Brien PC, Spry NA, Penniment M, Krawitz H, Williamson S, Bear J, Tripcony L: Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? Radiother Oncol, 52: 157-164, 1999.
31. Brizel DM, Wasserman TH, Henke M, Strnad V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W, Sauer R: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol, 18: 3339-3345, 2000.
32. Bourhis J, De Crevoisier R, Abdulkarim B, Deutsch E, Lusinchi A, Luboinski B, Wibault P, Eschwege F: A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys, 46: 1105-1108, 2000.
33. Peters LJ, Ang KK, Thames HD: Accelerated fractionation in the radiation treatment of head and neck cancer. Acta Oncol, 27: 185-194, 1988.
34. Trotti A: Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys, 47: 1-12, 2000.
35. Khalil AA, Bentzen SM, Bernier J, Saunders M, Horiot JC, van den Bogaert W, Cummings B, Dische S: Compliance to the prescribed dose and overall treatment time in five randomized clinical trials of altered fractionation in radiotherapy for head-and-neck carcinomas. Int J Radiat Oncol Biol Phys. 55: 568-575, 2003.
36. Geara FB, Peters LJ, Ang KK, Wike JL, Brock WA: Prospective comparison of in vivo normal cell radiosensitivity and normal tissue reactions in radiotherapy patients. Int J Radiat Oncol Biol Phys, 27: 1173-1179, 1993.
37. Terry NHA, Peters LJ: Predictive value of tumor cell kinetics parameters in radiotherapy: considerations regarding data production and analysis. J Clin Oncol, 13: 1833-1836, 1995.
38. Corvo' R, Giaretti W, Sanguineti G, Geido E, Orecchia R, Barra S, Margarino G, Bacigalupo A, Vitale V: Potential doubling time in head and neck tumors treated by primary radiotherapy: preliminary evidence for a prognostic significance in local control. Int J Radiat Oncol Biol Phys, 27: 1165-1172, 1993.
39. Antognoni P, Bignardi M, Cazzaniga LF, Poli M, Richetti A, Bossi A, Rampello G, Barbera F, Soatti C, Bardelli D, Giordano M, Danova M: Accelerated radiation therapy for locally advanced squamous cell carcinomas of the oral cavity and oropharynx selected according to tumor cell kinetics. A phase II multicenter study. Int J Radiat Oncol Biol Phys. 36: 1137-1145, 1996.
40. Wilson GD: Tpot and head and neck cancer: where are we now? Anticancer Res, 18: 4081-4086, 1998.
41. Begg AC, Haustermans K, Hart AM, Dische S, Saunders M, Zackrisson B, Gustaffson H, Coucke P, Paschoud N, Hoyer M, Overgaard J, Antognoni P, Richetti A, Bourhis J, Bartelink H, Horiot JC, Corvò R, Giaretti W, Awwad H, Shouman T, Jouffroy T, Maciorowski Z, Dobrowsky W, Struikmans H, Rugers D, Wilson GD: The value of cell kinetics parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother Oncol, 50: 13-23, 1999.
42. Haustermans K, Fowler JF: Is there a future for cell kinetics measurements using IdUrd or BdUrd? Int J Radiat Oncol Biol Phys, 49: 505-511, 2001.
43. Slevin NJ, West CML, Wilson GD, Hendry J: The potential benefit from individualised radiotherapy scheduling for head and neck tumours on the basis of both histological grade and kinetics. Radiother Oncol, 51: 109-111, 1999.
44. Corvò R, Antognoni P, Sanguineti G: Biological predictors of response to radiotherapy in head and neck cancer: recent advances and emerging perspectives. Tumori, 87: 355-363, 2001.
45. Withers HR: What Tpot is not. Int J Radiat Oncol Biol Phys, 35: 633-634, 1996.
46. Antognoni P, Terry NHA, Richetti A, Luraghi R, Tordiglione M, Danova M: The predictive role of flow cytometry-derived tumor potential doubling time (Tpot) in radiotherapy: open questions and future perspectives (Review). Int J Oncol, 12: 245-256, 1998.
47. Borgmann K, Roper B, El-Awady RA, Brackrock S, Bigalke M, Dork T, Alberti W, Dikomey E, Dahm-Daphi J: Indicators of late normal tissue response after radiotherapy for head and neck cancer: fibroblasts, lymphocytes, genetics, DNA repair, and chromosome aberrations. Radiother Oncol, 64: 141-152, 2002.
48. Andreassen CN, Alsner J, Overgaard J: Does variability in normal tissue reactions after radiotherapy have a genetic basis: where to look for it? Radiother Oncol, 64: 131-140, 2002.
49. Dobrowsky W, Dobrowsky E, Wilson GD: In vivo cell kinetic measurements in a randomized trial of continuous hyperfractionated accelerated radiotherapy with or without mitomycin C in head-and-neck cancer. Int J Radiat Oncol Biol Phys, 55: 576-582, 2003.
50. Fowler JF, Harari PM, Leborgne F, Leborgne JH: Acute radiation reactions in oral and pharyngeal mucosa. Tolerable levels in altered fractionation schedules. Radiother Oncol, 69: 161-168, 2003.
51. Baumann M, Holscher T, Begg AC: Towards genetic prediction of radiation responses: ESTRO's GENEPI project. Radiother Oncol, 69: 121-125, 2003.
52. Andreassen CN, Alsner J, Overgaard M, Overgaard J: Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol, 69: 127-135, 2003.
53. Brizel DM: Radiotherapy and concurrent chemotherapy for the treatment of locally advanced head and neck squamous cell carcinoma. Sem Radiat Oncol, 8: 237-246, 1999.